Calithera Biosciences (NASDAQ:CALA) Institutional Investor Positioning Change

Calithera Biosciences, Inc. (NASDAQ:CALA) Logo

Sentiment for Calithera Biosciences (NASDAQ:CALA)

Calithera Biosciences (NASDAQ:CALA) institutional sentiment increased to 0.91 in 2018 Q3. Its up 0.24, from 0.67 in 2018Q2. The ratio has increased, as 31 hedge funds increased and opened new positions, while 34 decreased and sold equity positions in Calithera Biosciences. The hedge funds in our partner’s database now hold: 18.95 million shares, up from 18.33 million shares in 2018Q2. Also, the number of hedge funds holding Calithera Biosciences in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 14 Reduced: 20 Increased: 23 New Position: 8.

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $163.94 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize SymbioscienceÂ’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

The stock decreased 0.23% or $0.01 during the last trading session, reaching $4.3. About 55,235 shares traded. Calithera Biosciences, Inc. (NASDAQ:CALA) has declined 49.90% since January 14, 2018 and is downtrending. It has underperformed by 49.90% the S&P500.

Analysts await Calithera Biosciences, Inc. (NASDAQ:CALA) to report earnings on March, 14. They expect $-0.48 EPS, down 54.84 % or $0.17 from last year’s $-0.31 per share. After $-0.52 actual EPS reported by Calithera Biosciences, Inc. for the previous quarter, Wall Street now forecasts -7.69 % EPS growth.

Bvf Inc Il holds 1.17% of its portfolio in Calithera Biosciences, Inc. for 2.54 million shares. Franklin Street Advisors Inc Nc owns 81,580 shares or 0.06% of their US portfolio. Moreover, Hikari Power Ltd has 0.05% invested in the company for 100,000 shares. The Pennsylvania-based Federated Investors Inc Pa has invested 0.02% in the stock. Quantitative Systematic Strategies Llc, a Connecticut-based fund reported 15,272 shares.

Calithera Biosciences, Inc. (NASDAQ:CALA) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.